TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12140003

Group type: EXPERIMENTAL
Intervention: Chronic Donepezil administration (5mg/day) for 11+/‐2.6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated AD patients)
Number of subjects: 25
Study: 10212779

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg in a single oral dose (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg once daily for 3 days (group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CPFX) 200 mg twice daily for 3 days (group C)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxcetil (CPDX-PR) 200 mg once daily for 3 days (group D)
Number of subjects: 120
Study: 7786823

Group type: EXPERIMENTAL
Intervention: Early alternating chemotherapy (ABABAB)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Late alternating chemotherapy (AAABBB)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Both early and late alternating chemotherapy
Number of subjects: 406
Study: 2078039

Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apraclonidine + Pilocarpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 468745

Group type: EXPERIMENTAL
Intervention: Frontalis EMG biofeedback
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Digit temperature biofeedback
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Digit temperature biofeedback plus Rational-Emotive Therapy (RET)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Self-monitoring of headache activity (waiting list)
Number of subjects: 24
Study: 29316994

Group type: EXPERIMENTAL
Intervention: 400 mg/d DHA during pregnancy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Maternal DHA status
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Child DHA intake and status
Number of subjects: 98
Study: 27228264

Group type: EXPERIMENTAL
Intervention: Enhanced couple‐focused group intervention (ECG)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Couples' support group (SG)
Number of subjects: 302
Study: 25370185

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) and fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) and placebo
Number of subjects: 0
Study: 23033886

Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (100 μg daily for 3 months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nonselenium-enriched yeast (control group, 3 months)
Number of subjects: 103
Study: 20534755

Group type: EXPERIMENTAL
Intervention: Polygonum cuspidatum extract (PCE) containing 40 mg resveratrol daily for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18674464

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High microemboli group
Number of subjects: 27
Study: 16158720

Group type: EXPERIMENTAL
Intervention: Combination of tymohexine and antrale
Number of subjects: 89
Study: 11961342

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10531162

Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX) 600 mg qd
Number of subjects: 504

Group type: COMPARATOR
Intervention: Clarithromycin (CLA) 500 mg bid
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Clarithromycin (CLA)
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Grepafloxacin (GFX) and Clarithromycin (CLA)
Number of subjects: 504
Study: 8941508

Group type: EXPERIMENTAL
Intervention: Simulated altitude (barometric pressure lowered to 432 +/- 2 mmHg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normobaric hypoxia (adding nitrogen to match inspired PO2 of altitude exposure)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxic hypobaria (lowering barometric pressure and adding oxygen to match inspired PO2)
Number of subjects: 9
Study: 1834144

Group type: EXPERIMENTAL
Intervention: Vapiprost (0.125 to 16 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7039437

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of cold dry air at -18 degrees C and 0% humidity
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Correlation between PD10 RHE and PC20
Number of subjects: 26
Study: 29974545

Group type: EXPERIMENTAL
Intervention: Long cyberbullying prevention program (10 weekly sessions)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Short cyberbullying prevention program (one day, four sessions)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 722
Study: 30347415

Group type: EXPERIMENTAL
Intervention: Synchronized pedaling with martial arts (2 sessions per week for 12 weeks)
Number of subjects: 53
Study: 27634489

Group type: EXPERIMENTAL
Intervention: Hughes Repair
Number of subjects: 800

Group type: COMPARATOR
Intervention: Standard mass closure
Number of subjects: 800
Study: 24760262

Group type: EXPERIMENTAL
Intervention: Basal and stimulated C-peptide levels
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Age and BMIZ
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 582

Group type: COMPARATOR
Intervention: HLA type and number of positive antibodies
Number of subjects: 582
Study: 22966077

Group type: EXPERIMENTAL
Intervention: Glucose feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inulin feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No supplementary WSC (control)
Number of subjects: 12
Study: 20591890

Group type: EXPERIMENTAL
Intervention: On-pump CABG (CPB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CPB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (OPCAB)
Number of subjects: 71
Study: 16480971

Group type: EXPERIMENTAL
Intervention: Phonological overlap with strong orthographic overlap (e.g., dream-gleam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phonological overlap with weak orthographic overlap
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phonological priming in pseudoword detection task
Number of subjects: 0
Study: 15700891

Group type: EXPERIMENTAL
Intervention: Exenatide 0.02-0.2 microg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12388963

Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg every 4 hours)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (200 microg every hour for 3 hours followed by 400 microg every 4 hours)
Number of subjects: 114
Study: 9915282

Group type: EXPERIMENTAL
Intervention: Standard dose of dialysis (target eKt/V 1.05)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: High dose of dialysis (target eKt/V 1.45)
Number of subjects: 426
Study: 7780250

Group type: EXPERIMENTAL
Intervention: Hypotonic oral rehydration solution (ORS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard WHO‐ORS
Number of subjects: 60
Study: 1399929

Group type: EXPERIMENTAL
Intervention: High-dose ciprofloxacin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Azlocillin and netilmicin
Number of subjects: 133
Study: 3160356

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of atenolol and nitrendipine (100 mg and 20 mg respectively, once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination therapy (Atenolol + Nitrendipine)
Number of subjects: 40
Study: 30934881

Group type: EXPERIMENTAL
Intervention: 20,000 IU of vitamin D3/week for 12 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 200
Study: 29389505

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring general well-being, sense of coherence, self-efficacy of diabetes management, experiences of diabetes management during breastfeeding
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring general well-being
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring sense of coherence
Number of subjects: 155
Study: 27094189

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg per day (with option to increase to 40 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (one capsule)
Number of subjects: 62
Study: 25082363

Group type: EXPERIMENTAL
Intervention: Quality assurance measures during prostate radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major protocol variations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level III phantom-based dosimetry study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Set-up accuracy study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher-accruing centres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance variables
Number of subjects: 0
Study: 24500507

Group type: EXPERIMENTAL
Intervention: Weight retention in postpartum period among women who were overweight (9.9 ± 7.7 kg)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Weight retention more than 10 kg in postpartum
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Comparison of overweight prevalence
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Association of factors with weight retention
Number of subjects: 715
Study: 21607780

Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen 2 mg/kgBW
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: i.v. paracetamol 15 mg/kgBW
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of i.v. ketoprofen and i.v. paracetamol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (paracetamol)
Number of subjects: 120
Study: 18281734

Group type: EXPERIMENTAL
Intervention: 20 mg of omeprazole
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg of omeprazole
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 200 mg of ritonavir with 800 mg of indinavir and 40 mg of omeprazole
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 17171191

Group type: EXPERIMENTAL
Intervention: Extended-release zolpidem
Number of subjects: 0
Study: 14586908

Group type: EXPERIMENTAL
Intervention: Ambulatory training of strength, functional performance, and balance 3 times a week for 3 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo activities
Number of subjects: 57
Study: 10722989

Group type: EXPERIMENTAL
Intervention: Physician advice on physical activity
Number of subjects: 54
Study: 9643668

Group type: EXPERIMENTAL
Intervention: Terazosin (TER) 1 mg, 2 mg, and 5 mg once daily in the evening for 15 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg once daily after breakfast for 15 days
Number of subjects: 50
Study: 8196850

Group type: EXPERIMENTAL
Intervention: Fluoxetin (20 mg/die) and cyclobenzaprine (10 mg/die)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cyclobenzaprine (10 mg/die)
Number of subjects: 21
Study: 3286577

Group type: EXPERIMENTAL
Intervention: Oral acyclovir (400 mg three times a day on Days -6 to +14 and 200 mg three times a day on Days +15 to +90 for adults; 500 mg/m2 per day divided into three doses on Days -6 to +14 and 250 mg/m2 per day divided into three doses on Days +15 to +90 for children)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (14 untreated HSV-seropositive BMT recipients)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 34
Study: 29467019

Group type: EXPERIMENTAL
Intervention: STAR care pathway intervention (assessment clinic appointment and up to six telephone follow-up calls over 12 months)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: STAR care pathway intervention
Number of subjects: 381

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 381
Study: 27317249

Group type: EXPERIMENTAL
Intervention: Educational video instruction
Number of subjects: 502

Group type: COMPARATOR
Intervention: Non-video (control) group
Number of subjects: 502
Study: 25314058

Group type: EXPERIMENTAL
Intervention: Higher β-carotene levels
Number of subjects: 29046

Group type: EXPERIMENTAL
Intervention: Higher retinol levels
Number of subjects: 29046

Group type: EXPERIMENTAL
Intervention: Higher α-tocopherol levels
Number of subjects: 29046
Study: 22649258

Group type: EXPERIMENTAL
Intervention: Blended soup meal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Solid/liquid meal
Number of subjects: 40
Study: 20595658

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study: 18821888

Group type: EXPERIMENTAL
Intervention: Pelvic wedge positioning (group W)
Number of subjects: 78

Group type: COMPARATOR
Intervention: 20 degrees Trendelenberg tilt (group T)
Number of subjects: 78
Study: 15668621

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit
Number of subjects: 3297

Group type: COMPARATOR
Intervention: Standard HIV testing and counseling in 2 visits
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among men)
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among men who had sex with men)
Number of subjects: 3297

Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among persons with no STDs at enrollment)
Number of subjects: 3297
Study: 12059988

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg day(‐1))
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g day(‐1))
Number of subjects: 52
Study: 7660770

Group type: EXPERIMENTAL
Intervention: Sonography group (39 women)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopy group (41 women)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) results
Number of subjects: 80
Study: 2607126

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study: 31254485

Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Transparent hood-assisted colonoscopy (TAC)
Number of subjects: 513
Study: 27693108

Group type: COMPARATOR
Intervention: RBT
Number of subjects: 135

Group type: COMPARATOR
Intervention: RBTRH
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: RBTSPRH
Number of subjects: 135
Study: 25946938

Group type: EXPERIMENTAL
Intervention: Acupressure at true points (ST36, SP6, LI4)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group (touching at the same points)
Number of subjects: 100
Study: 23645311

Group type: EXPERIMENTAL
Intervention: Real modulation (R)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham modulation (S)
Number of subjects: 32
Study: 21325151

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (cumulative dose, 0.4 μg/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 20031900

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 17802
Study: 17804382

Group type: EXPERIMENTAL
Intervention: Class 1 (lower trauma exposure)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Class 2 (higher trauma exposure)
Number of subjects: 149
Study: 15562081

Group type: EXPERIMENTAL
Intervention: Midline approach
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 50
Study: 11567703

Group type: EXPERIMENTAL
Intervention: Warmed patients (local and systemic warming)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Non-warmed patients (standard group)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Warmed patients
Number of subjects: 421

Group type: COMPARATOR
Intervention: Non-warmed patients
Number of subjects: 421
Study: 9593014

Group type: EXPERIMENTAL
Intervention: HDCV three-injection regimen
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PVRV three-injection regimen
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Booster injection at 1 year
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Antibody titers 2 weeks after the 1‐year booster
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Good responders (titers > or = 30 IU/mL)
Number of subjects: 312
Study: 7947412

Group type: EXPERIMENTAL
Intervention: Chronic schizophrenic patients
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alcoholic controls
Number of subjects: 72
Study: 2698461

Group type: EXPERIMENTAL
Intervention: Captopril (2 x 12.5 mg) in addition to standard treatment (digitalis and diuretics)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard treatment (digitalis and diuretics)
Number of subjects: 8
Study: 1071872

Group type: EXPERIMENTAL
Intervention: Independent reading of ECG-Case summary sheets (2 or 4 occasions)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reference to coronary arteriographic information
Number of subjects: 8
Study: 31941696

Group type: EXPERIMENTAL
Intervention: Planned early delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study: 31348088

Group type: EXPERIMENTAL
Intervention: Random Forests (RF) classifier with 10,000 trees, each tree using 15 randomly selected cases and 20 randomly selected features (SUV ratio per region of interest)
Number of subjects: 57
Study: 28845908

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 35
Study: 25409838

Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (LM)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pneumatic dilatation (PD)
Number of subjects: 53
Study: 23401434

Group type: EXPERIMENTAL
Intervention: Low-dose helical computed tomography (LDCT)
Number of subjects: 53454

Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 53454
Study: 22152404

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99
Study: 19149880

Group type: EXPERIMENTAL
Intervention: Active Physical Therapy (APT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Passive Physical Therapy (PPT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Activity as Usual (AAU)
Number of subjects: 70
Study: 17189096

Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg once a day for 3 days)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Moxifloxacin (400mg once a day for 5 days)
Number of subjects: 342
Study: 15124700

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (MT) consisting of mercaptopurine and cytarabine for 18 months
Number of subjects: 309

Group type: COMPARATOR
Intervention: No maintenance therapy (control group)
Number of subjects: 309
Study: 12548362

Group type: EXPERIMENTAL
Intervention: Apo‐TD (transdermal apomorphine)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L‐dopa plus Apo‐TD
Number of subjects: 21

Group type: COMPARATOR
Intervention: L‐dopa alone or L‐dopa plus oral dopamine‐agonists
Number of subjects: 21
Study: 9638687

Group type: EXPERIMENTAL
Intervention: Prenatal cigarette exposure
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Prenatal marihuana exposure
Number of subjects: 131
Study: 8030657

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day; group 1)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: High-dose intravenous gammaglobulin (400 mg/kg on days 1 through 5; group 2)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination of both agents (group 3)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Oral prednisone (group 1)
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-dose intravenous gammaglobulin (group 2)
Number of subjects: 43
Study: 2606207

Group type: EXPERIMENTAL
Intervention: Auditory and tactile cues
Number of subjects: 37

Group type: COMPARATOR
Intervention: Auditory cues
Number of subjects: 37
Study: 1106739

Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidocaine with adrenaline 1:200,000
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study: 31079356

Group type: EXPERIMENTAL
Intervention: Yimitasvir 30 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yimitasvir 100 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yimitasvir 200 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yimitasvir 400 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yimitasvir 100 mg once daily for 7 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Yimitasvir 200 mg once daily for 7 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standardized high-fat meal
Number of subjects: 56
Study: 28384237

Group type: EXPERIMENTAL
Intervention: Need-supportive physical activity intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 48
Study: 25223731

Group type: EXPERIMENTAL
Intervention: 10 mg selisistat
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 100 mg selisistat
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 24235227

Group type: EXPERIMENTAL
Intervention: Vectormune FP MG vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FMG revaccination at 45 weeks of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: FMG vaccination in M. gallisepticum-clean hens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0